

ASX Announcement

Invion Limited (ASX Code IVX)

Section 708A Cleansing Statement

5 March 2026

This notice is given by Invision Limited (**Company**) under Section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company hereby confirms that:

- (a) the Company issued 11,318,060 fully paid ordinary shares upon the maturity of 72,024 unlisted convertible notes (**Shares**) today;
- (b) the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (c) the Company is providing this notice under paragraph 5(e) of Section 708A of the Corporations Act;
- (d) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:
 - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (ii) section 674 of the Corporations Act as it applies to the Company; and
- (e) as at the date of this announcement, other than as set out below there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act.

Invion is in discussions with potential contract research organisations and capital providers with a view to expanding its clinical trial and research programme across additional indications. Invion is also in discussions with third parties regarding potential non-human applications for its compounds. Apart from those already disclosed to the market, no binding or definitive agreements have been reached and there is no guarantee that any such transactions will proceed.

This announcement is authorised for release by the Board of Directors of Invision Limited.

Investor and Media enquiries:

Thian Chew (Chairman)

T: +61 3 8618 6843

E: investor@inviongroup.com

Brendon Lau (Investor & Media Relations)

T: +61 409 341 613

E: brendon@vantagepointpartners.com.au



About Invion

Invion is a life-science company that is leading the global research and development of Photosoft™ technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the Photosoft™ technology. Research and clinical trials are funded by the technology licensor, RMW Cho Group Limited and its affiliates, via an R&D services agreement with the Company. Invion is listed on the ASX (ASX: IVX). This announcement was approved for release by Thian Chew, Chairman of the Board. For further information please contact Investor@inviongroup.com).

About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.